Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

BACKGROUND: We report on the results of a phase II clinical trial of Panagen (tablet form of fragmented human DNA preparation) in breast cancer patients (placebo group n = 23, Panagen n = 57). Panagen was administered as an adjuvant leukoprotective agent in FAC and AC chemotherapy regimens. Pre-clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Proskurina, Anastasia S., Gvozdeva, Tatiana S., Potter, Ekaterina A., Dolgova, Evgenia V., Orishchenko, Konstantin E., Nikolin, Valeriy P., Popova, Nelly A., Sidorov, Sergey V., Chernykh, Elena R., Ostanin, Alexandr A., Leplina, Olga Y., Dvornichenko, Victoria V., Ponomarenko, Dmitriy M., Soldatova, Galina S., Varaksin, Nikolay A., Ryabicheva, Tatiana G., Uchakin, Peter N., Rogachev, Vladimir A., Shurdov, Mikhail A., Bogachev, Sergey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990870/
https://www.ncbi.nlm.nih.gov/pubmed/27538465
http://dx.doi.org/10.1186/s12885-016-2711-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990870/
https://www.ncbi.nlm.nih.gov/pubmed/27538465
http://dx.doi.org/10.1186/s12885-016-2711-5

Ejemplares similares